Abstract
Cancer is probably the most complex of all diseases as it is associated with mutation in the genomes. Mutation is caused by certain reasons like toxic chemicals, poisonous gases, radiations, etc. Cancer-causing genes are called as oncogenes (Bcl-2, C-myc, foc, jun, HER-2/neu/c-erb-2), and the genes which suppress cancer are known as suppressor genes (Bax, cx32, cx43, p53, etc). During cell cycle, only healthy cells can enter from G phase to cytokinesis phase, and unhealthy cells undergo apoptosis which is under the control of p53 gene (“guardian of DNA”). Mutation in this gene affects the whole cycle, which may result in the formation of tumors. According to the recent studies, mutation in genes like EGFR, PSA, and BRCA may lead to lung, prostate, and breast cancer, respectively. Our work is based on reliable data collected from various cancer databases like Integrative Oncogenomics Cancer Browser, Mouse Retrovirus Tagged Cancer Gene Database, the CEO Life Sciences Consortium, COSMIC, IntOGen, International Cancer Genome Consortium, CAB Abstract, J-GATE, ERIC, ProQuest, and INMEDPLAN and websites such as www.jstor.org, www.sciencedirect.com, www.ncbi.nlm.nih.gov/pubmed/, etc. The objective of this chapter is to state the role of genes in various cancers. Moreover, the information presented in this report may help the “to be” oncologists to learn more about the causes and therapies for cancer treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Burgering BM, Medema RH (2003) Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 73:689–701
Chin L, Andersen JN, Futreal PA (2011) Cancer genomics: from discovery science to personalized medicine. Nat Med 17(3):297
Collak FK, Yagiz K, Luthringer DJ, Erkaya B, Cinar B (2012) Threonine- 120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1. J Biol Chem 287:23698–23709
Davies AA, Masson JY, McIlwraith MJ, Stasiak AZ, Stasiak A, Venkitaraman AR, West SC (2001) Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7(2):273–282
Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu Z (2007) Phosphorylation of b-catenin by AKT promotes b-catenin transcriptional activity. J Biol Chem 282:11221–11229
Green DR, Llambi F (2014) Cell death signaling. Cold Spring Harb Perspect Biol:a006080
Harrison DA (2012) The Jak/STAT pathway. Cold Spring Harb Perspect Biol 4:a011205
Hemmings BA, Restuccia DF (2012) PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 4:a011189
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13:714–726
Kim J, Parrish AB, Kurokawa M, Matsuura K, Freel CD, Andersen JL, Johnson CE, Kornbluth S (2012) Rsk-mediated phosphorylation and 14-3-31 binding of Apaf-1 suppresses cytochrome c-induced apoptosis. EMBO J 31:1279–1292
Korkaya H, Paulson A, Charafe-Jauffret E, Ginestier C, BrownM DJ, Clouthier SG, Wicha MS (2009) Regulation of mammary stem/ progenitor cells by PTEN/Akt/b-catenin signaling. PLoS Biol 7:e1000121
Lito P, Rosen N, Solit DB (2013) Tumor adaptation and resistance to RAF inhibitors. Nat Med 19:1401–1409
Morrison DK (2012) MAP kinase pathways. Cold Spring Harb Perspect Biol 4:a011254
Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N, Gotoh Y (2002) Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 277:21843–21850
Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Ye K (2010) A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278):191
Renoir JM, Marsaud V, Lazennec G (2013) Estrogen receptor signaling as a target for novel breast cancer therapeutics. Biochem Pharmacol 85:449–465
Richardson CJ, Schalm SS, Blenis J (2004) PI3-kinase and TOR: PIKTORing cell growth. Semin Cell Dev Biol 15:147–159
Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45:1446–1451
Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR (2000) Multiple Ras-dependent phosphorylation pathways regulateMyc protein stability. Genes Dev 14:2501–2514
Sever R, Brugge JS (2015) Signal transduction in cancer. Cold Spring Harb Perspect Med 5(4):a006098
Shen HM, Tergaonkar V (2009) NFkB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 14:348–363
Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45:1439–1445
Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, Li F, Tsang S, Wu K, Wu H (2012) Single-cell exome sequencing reveals singlenucleotide mutation characteristics of a kidney tumor. Cell 148:886–895
Zhang X, Tang N, Hadden TJ, Rishi AK (2011) Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 1813:1978–1986
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Koul, B. (2019). Cancer Genomics. In: Herbs for Cancer Treatment. Springer, Singapore. https://doi.org/10.1007/978-981-32-9147-8_1
Download citation
DOI: https://doi.org/10.1007/978-981-32-9147-8_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9146-1
Online ISBN: 978-981-32-9147-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)